The board of Chordate Medical Holding AB (publ) ("Chordate") has today decided to start the process of changing trading venue to Nasdaq First North Growth Market in Stockholm. The company's shares are currently traded on NGM Nordic SME.
The Board believes that a change of trading venue for the company's shares to Nasdaq First North Growth Market will increase the knowledge of the company both in Sweden and internationally, making it easier for industrial investors to become shareholders, and have a positive impact on the company's relationships with partners and potential customers.
Overall, a change of trading venue is considered to be positive for Chordate's development and completion of the stated exit strategy. Nasdaq First North Growth Market is Nasdaq's European growth market, with the same legal status as NGM Nordic SME. Shareholders in Chordate will not have to take any action in the event of a change of trading venue.
We are grateful for the cooperation and the good dialogue between the company and NGM during the period the company's share has been listed on NGM Nordic SME.
Västra Hamnen Corporate Finance AB is Chordate's advisor regarding the planned list change and Certified Adviser.
Wistrand Advokatbyrå AB is Chordate's legal advisor.
This disclosure was submitted for publication, through the contact person below, on September 14th, 2021, at 16:30 am CET.
For more information, please contact:
Anders Weilandt, VD
Phone: +46 (0) 733 87 42 77
The following documents can be retrieved from beQuoted
Chordate Medical Holding AB (publ) is a medical technology company that for over ten years has developed, patented and CE-marked a new neuromodulation treatment technology for chronic nasal congestion (rhinitis) and chronic migraine. The company offers its product via distributors to clinics and hospitals in selected European markets, Israel and Saudi Arabia. Chordate Medical's share is listed on the Nordic Growth Market NGM – SME (ticker: CMH). Read more at https://www.chordate.com/en/